Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines

Chinese Medical Journal

Volumn 124, Issue 3, 2011, Pages 419-422

  Si, Shuang ^a   Liao, Quan ^a   Zhao, Yu Pei ^a   Hu, Ya ^a   Zhang, Qiang ^a   You, Li Li ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Chemosensitivity; Deoxycytidine kinase gene; Gemcitabine; Pancreatic neoplasm; Single nucleotide polymorphism

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DRUG SENSITIVITY; GENE ACTIVITY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; GENOTYPE; HUMANS; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79551709203     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.03.018     Document Type: Article

References (17)

1. Zhou J, Enewold L, Stojadinovic A, Clifton GT, Potter JF, Peoples GE, et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control 2010; 21: 853-861.
2. Amptoulach S, Kalaitzakis E, Azam F. Adjuvant chemotherapy should be used as the standard of care for resectable pancreatic cancer. Cancer Ther 2009; 7: 227-233.
3. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41: 77-88.
4. Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14: 759-768.
5. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 2006; 62: 681-684.
6. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-329.
7. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323: 935-945.
8. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008; 23: 379-384.
9. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006; 5: 787-796.
10. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5): 7-12.
11. Song JJ, Walker S, Chen E, Johnson EE 2nd, Spychala J, Gribbin T, et al. Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc Natl Acad Sci U S A 1993; 90: 431-434.
12. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, et al. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001; 7: 3263-3268.
13. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371-376.
14. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004; 4: 307-314.
15. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
16. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 2007; 97: 145-151.
17. Kocabas NA, Aksoy P, Pelleymounter LL, Moon I, Ryu JS, Gilbert JA, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008; 36: 1951-1959.